News

Home / News

Announcement on behalf of major subsidiary,TOP Biological Technology Company Limited, regarding the release of non-competition

2024.4.24

1.Date of the shareholders' meeting resolution:2024/04/24

2.Name and title of the managerial officer with permission to engage in competitive conduct:
(1)TSH Biopharm Corporation Limited;Director
(2)Representative of TSH Biopharm Corporation Limited:Sze-Yuan Yang;Director
(3)Jui-Wen Wu;Director
(4)Lai-Shou Su;Director
(5)Min-Li Wei;Director
(6)Shih-Cheng Lai;Director

3.Items of competitive conduct in which the officer is permitted to engage:Similiar scope of business of director of management

4.Period of permission to engage in the competitive conduct: The period of being director of the Company.

5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):
(1)936,790 in total voting rights were represented at the time of voting;
(2)936,790 voting right presented for, 100% of total voting rights;
(3)0 voting right presented against, 0% of total voting rights;
(4)0 invalid votes, 0% of total voting rights;
(5)0 voting right presented abstention and not voting,0% of total voting rights;
(6)This proposal was approved as proposed as affirmative rights higher than statutory ones.

6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below):
Representative of TSH Biopharm Corporation Limited:Sze-Yuan Yang;Director

7.Company name of the mainland China enterprise and the officer’s position in the enterprise: Director of CHUANGYI (SHANGHAI) TRADING CO., LTD.

8.Address of the mainland China enterprise: Room 106, Building 3, No. 507, Huajing Road, Shanghai.

9.Operations of the mainland China enterprise: Trade of dietary supplements.

10.Impact on the company’s finance and business:None

11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio:None

12.Any other matters that need to be specified:None